1 February 2021
Session 1: Overview of targeting DDR dysfunction in cancer
Date: 1 February 2021
Time: 12:00pm (GMT) | 07:00am (EDT) | 8:00pm (CST Asia)
|
Speaker |
Presentation Topic |
Time (GMT) |
|
Keynote Speaker |
Targeting DNA damage response pathway basic mechanisms and translational implications |
12:00pm – 12:45pm |
1 February 2021
Session 2: DNA damage cell cycle checkpoints
Date: 1 February 2021
Time: 12:45pm (GMT) | 07:45am (EDT) | 8:45pm (CST Asia)
|
Speaker |
Presentation Topic |
Time (GMT) |
| Chair and plenary speaker Prof. Dr. Karlene A. Cimprich |
The Causes and Consequences of Replication Stress |
12:45pm - 13:15pm |
|
Dr. Ruth Thompson |
A novel DNA damage checkpoint in mitosis |
13:15pm - 13:30pm |
|
Dr. Gro Elise Rødland |
Differential effects of combined ATR/WEE1 |
13:30pm - 13:45pm |
|
Dr. Shan Yan |
Distinct mechanisms of ATR-Chk1 DNA damage response pathway in response to DNA single-strand break |
13:45pm - 14:00pm |
1 February 2021
Session 3: DNA repair, defects in cancer and their exploitation
Date: 1 February 2021
Time: 14:30pm (GMT) | 09:30m (EDT) | 10:45pm (CST Asia)
|
Speaker |
Presentation Topic |
Time (GMT) |
|
Chair and plenary speaker |
Targeting ATM-deficient cancers with PARP inhibitors |
14:30pm – 15:00pm |
|
Dr. Laura Monaghan |
KDM4A inhibition sensitises Acute Myeloid Leukaemia cells to PARP inhibitors through impairing Non-Homologous End Joining pathway and enhancing PARP trapping |
15:00pm – 15:15pm |
|
Dr. David King |
MYCN over-expression in Neuroblastoma potentiates PARP inhibitor induced radiosensitization |
15:15pm – 15:30pm |
|
Dr. Mats Ljungman |
Specific induction of DSBs in cancer cells by targeting chromosome rearrangements with CRISPR Technology |
15:15pm – 15:30pm |
2 February 2021
Session 4: MMR defects, mutator phenotype
Date: 2 February 2021
Time: 12:00pm (GMT) | 07:00am (EDT) | 8:00pm (CST Asia)
|
Speaker |
Presentation Topic |
Time (GMT) |
|
Chair and plenary speaker |
Targeting DNA MMR loss as a therapeutic strategy in cancer |
12:00pm – 12:30pm |
|
Dr. Tuyen Dang |
Elucidating the role of XRN2-mediated DNA repair programs |
12:30pm – 12:45pm |
|
Dr. Victoria Dunne |
Synergistic activity of DNA damage response kinase inhibitors in combination with the targeted alpha therapy radium-223 dichloride for metastatic castration-resistant prostate cancer |
12:45pm – 13:00pm |
|
Dr. Carolina Velázquez |
Exploiting DNA Repair Defect in Triple Negative Brest Cancer Using CDK Inhibition Strategy |
13:00pm – 13:15pm |
2 February 2021
Session 5: SUMO and Ubiquitination and other epigenetic and post-translational mechanisms
Date: 2 February 2021
Time: 14:00pm (GMT) | 09:00am (EDT) | 10:00pm (CST Asia)
|
Speaker |
Presentation Topic |
Time (GMT) |
| Chair Dr. Ruth Thompson |
N/A |
|
|
Plenary speaker |
|
14:00pm – 14:30pm |
|
Dr. Yi Sheng |
An Integrated Structure-based Approach for the Development of MDM2 inhibitors |
14:30pm – 14:45pm |
|
Dr. Alexandre Maréchal |
SMARCAL1 Ubiquitylation Controls its Association with RPA-ssDNA and Promotes Fork Stability |
14:45pm – 15:00pm |
|
Dr. Tham Thi Nguyen |
Epigenetic deregulation of nuclear transport impacts DNA repair capacity and treatment resistance in glioblastoma |
15:00pm – 15:15pm |
3 February 2021
Session 6: Targeting with immune checkpoint inhibitors
Date: 3 February 2021
Time: 12:00pm (GMT) | 07:00am (EDT) | 8:00pm (CST Asia)
|
Speaker |
Presentation Topic |
Time (GMT) |
| Chair and plenary speaker Dr. Juanita Suzanne Lopez |
Making invisible tumours visible – what next after Immune Checkpoint Inhibitors? |
12:00pm - 12:30pm |
|
Dr. Cucchi Danilo |
Mechanistic investigation of response to immune checkpoint blockade upon DNA Damage |
12:30pm - 12:45pm |
|
Dr. Jing Zhang |
Anti-inflammatory combinatorial therapy to enhance killing efficacy with patient-derived preclinical models |
12:45pm - 13:00pm |
|
Dr. Jian Li |
Depleting upregulated DNA polymerase theta (pol θ) in esophageal squamous cell carcinoma (ESCC) inhibits tumor growth, promotes genome instability, and induces ISGs expression through cGAS activation |
13:00pm - 13:15pm |
3 February 2021
Session 7: Overview and use of biomarkers in clinical trials
Date: 3 February 2021
Time: 14:00pm (GMT) | 09:00am (EDT) | 10:00pm (CST Asia)
|
Speaker |
Presentation Topic |
Time (GMT) |
|
Chair and plenary speaker |
A moving target - the use of predictive biomarkers in the targeting the DNA damage response in cancer |
14:00pm – 14:30pm |
|
Dr. Françoise Dantzer |
The therapeutic significance of PARP3 inhibition in highly aggressive cancers |
14:30pm – 14:45pm |
|
Dr. Jason Parsons |
Targeting the cellular DNA damage response following proton beam therapy |
14:45pm – 15:00pm |
|
Prof. Dr. Michael Hausmann |
Space and time in the universe of the cell nucleus after ionizing radiation attacks: a comparison of cancer and non-cancer cell response |
15:00pm – 15:15pm |